AXQ Capital LP Has $175,000 Stock Holdings in ImmunityBio, Inc. $IBRX

AXQ Capital LP boosted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 263.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 71,300 shares of the company’s stock after purchasing an additional 51,678 shares during the quarter. AXQ Capital LP’s holdings in ImmunityBio were worth $175,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IBRX. Armistice Capital LLC bought a new position in ImmunityBio during the second quarter worth about $20,497,000. Vanguard Group Inc. increased its stake in ImmunityBio by 26.8% during the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after purchasing an additional 5,837,898 shares in the last quarter. AlphaCore Capital LLC bought a new position in ImmunityBio in the second quarter valued at approximately $7,854,000. Geode Capital Management LLC boosted its holdings in shares of ImmunityBio by 34.7% in the second quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock valued at $15,254,000 after buying an additional 1,487,849 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of ImmunityBio by 347.7% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,028,921 shares in the last quarter. 8.58% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IBRX has been the subject of a number of research analyst reports. BTIG Research upped their target price on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Jefferies Financial Group upped their price target on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. HC Wainwright lifted their price objective on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday. Finally, The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a report on Monday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.60.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced completion of enrollment in its pivotal randomized Phase 2 trial of ANKTIVA plus BCG vs BCG alone in BCG‑naïve NMIBC CIS — early completion reduces timeline uncertainty for a potential label‑expanding readout and supports commercial upside for ANKTIVA. Article Title
• Positive Sentiment: Analyst/valuation commentary highlights trial progress and strong ANKTIVA commercial momentum — positive narratives that can support higher forward earnings expectations and investor confidence. Article Title
• Neutral Sentiment: ImmunityBio will host a business update and review FY‑2025 financial results on March 3 — the call could drive volatility depending on revenue, guidance, and clinical updates management provides. Article Title
• Neutral Sentiment: HC Wainwright published a Q1 earnings forecast for ImmunityBio — analyst forecasts and any accompanying model changes will influence near‑term analyst sentiment and target‑price revisions. Article Title
• Negative Sentiment: Director Barry Simon sold 75,000 shares at an average price of $12.01 (disclosed Feb 24) — insider selling can be interpreted by some investors as a signal to reduce exposure, contributing to downward pressure. Article Title
• Negative Sentiment: Reports cite significant intraday profit‑taking (one article notes a ~17% drop after an intraday high) and coverage pointing to a ~7% decline — these articles reflect short‑term selling and headline‑driven volatility that can amplify swings in the stock. Article Title Article Title

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $9.78 on Friday. ImmunityBio, Inc. has a 52-week low of $1.83 and a 52-week high of $12.43. The company has a market capitalization of $10.05 billion, a P/E ratio of -25.74 and a beta of 0.16. The company has a 50-day simple moving average of $5.27 and a 200 day simple moving average of $3.38.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. As a group, equities analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Insider Buying and Selling at ImmunityBio

In related news, Director Christobel Selecky sold 50,000 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 501,967 shares of company stock worth $4,466,412. Corporate insiders own 69.48% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.